Asensus Surgical Announces Installation of Senhance Surgical System at Evangelical Hospital Goettingen-Weende
August 31 2022 - 6:55AM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced the installation of a Senhance® Surgical System in
the General Surgery Department of Evangelical Hospital
Goettingen-Weende of Göttingen, Germany. This agreement to lease
and utilize a Senhance® Surgical System was one of two announced by
the Company on August 8, 2022.
“Goettingen-Weende has a significant laparoscopic program within
their general surgery department. We are excited to bring the
benefits of Senhance’s digital laparoscopy and Performance-Guided
Surgery to these experienced surgeons,” said Anthony Fernando,
Asensus Surgical President and CEO. “We look forward to
collaborating with the Goettingen-Weende team to work towards
increasing utilization of their Senhance system to help provide
enhanced care to their patients.”
The Senhance Surgical System’s open-platform
architecture allows for seamless integration of surgeon preference
tools, including the 3DHD visualization system.
Asensus Surgical's technology platform, Senhance Surgical
System, is the first of its kind digital laparoscopic platform. It
leverages augmented intelligence to provide unmatched performance
and patient outcomes through machine learning. Senhance goes beyond
the typical surgical robotic systems, providing surgical assurance
through haptic feedback, eye-tracking camera control, and 3D
visualization, and is the first platform to offer 3mm instruments
(the smallest instrument available in the world on a robotic
surgical platform). The Senhance Surgical System is powered by the
Intelligent Surgical Unit™ (ISU™). The ISU enables machine
vision-driven control of the camera for a surgeon by responding to
commands and recognizing certain objects and locations in the
surgical field. It allows a surgeon to change the visualized field
of view using the movement of their instruments. The newest ISU
features expand upon these capabilities and introduce more advanced
features including: 3D measurement, digital tagging, image
enhancement, and enhanced camera control based on real-time data
from anatomical structures while performing surgery.
“The Senhance platform is a compelling new option for our
surgeons and it is an important addition to our laparoscopic
department, which provides a large number of minimally invasive
surgeries,” said Professor Claus Langer, Head of the General,
Visceral, and Thoracic Surgery Department. “This cutting-edge
robotic technology enhances what a surgeon can see and do during
surgery which greatly benefits our patients.”
About Evangelical Hospital Goettingen-WeendeThe
Evangelical Hospital Goettingen-Weende is a tertiary care hospital
with a total of 601 beds and 14 operating rooms. The hospital
performs 10,500 in-hospital surgeries and 3,500 ambulant surgeries
per year (all specialties), and is located in Göttingen-Weende,
Göttingen / Neu-Mariahilf and Bovenden-Lenglern. For more
information, visit https://www.ekweende.de/
About Asensus Surgical, Inc.Asensus Surgical,
Inc. is digitizing the interface between the surgeon and patient to
pioneer a new era of Performance-Guided Surgery by unlocking
clinical intelligence for surgeons to enable consistently superior
outcomes and a new standard of surgery. This builds upon the
foundation of Digital Laparoscopy with the Senhance Surgical System
powered by the Intelligent Surgical Unit (ISU) to increase surgeon
control and reduce surgical variability. With the addition of
machine vision, augmented intelligence, and deep learning
capabilities throughout the surgical experience, we intend to
holistically address the current clinical, cognitive and economic
shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
Follow Asensus
- Email Alerts: https://ir.asensus.com/email-alerts
- LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
- Twitter: https://twitter.com/AsensusSurgical
- YouTube: https://www.youtube.com/c/transenterix
- Vimeo: https://vimeo.com/asxc
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and Evangelical Hospital Goettingen-Weende
initiating a program with the Senhance System. These statements and
other statements regarding our future plans and goals constitute
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control and which may cause results to differ materially from
expectations and include whether the Senhance Surgical System will
help provide enhanced care to patients of Evangelical Hospital
Goettingen-Weende. For a discussion of the risks and uncertainties
associated with the Company’s business, please review our filings
with the Securities and Exchange Commission (SEC), including our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the SEC on February 28, 2022 and our other filings we
make with the SEC. You are cautioned not to place undue reliance on
these forward looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the origination date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
INVESTOR CONTACT:Mark Klausner or Mike Vallie,
443-213-0499invest@asensus.comorMEDIA
CONTACT:Lauren Stredler, 847-271-6891CG
Lifelstredler@cglife.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/6220d01a-2172-4b18-8321-92ae388f4391
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Apr 2023 to Apr 2024